Form 8-K Journey Medical Corp For: Aug 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
B.Riley Reiterates Buy Rating on Journey Medical Corp. (DERM)
August 13, 2024 6:55 AM EDTB.Riley analyst Kalpit Patel reiterated a Buy rating and $8.00 price target on Journey Medical Corp. (NASDAQ: DERM).
The analyst comments "Journey Medical (DERMBuy, $8 PT) reported 2Q earnings, with top-line revenues of $14.9M (vs. our $13.3M estimate), likely signaling stabilization in its dermatology-focused... More
